
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
CRO Aptus Clinical has been appointed as a supplier for clinical services by the Cell and Gene Therapy Catapult (CGTC). As an early-phase CRO, its role is to support development and delivery of advanced therapy studies in the UK and Europe. Through this partnership, Aptus Clinical will primarily provide dedicated site set-up and monitoring of investigational sites for the CGTC’s collaborators.
Read the full release






